Emcure Pharmaceuticals Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/kf99soyfab508l7qe2gknze9.pdf

Key Takeaways


Domestic Business: Sanofi Integration Offsets Acute Weakness

Satish Mehta: "Gagan, it's very difficult to hazard a guess. There are lots of theories which are being flouted around. Somebody says that generic business is taking their share, Jan Aushadhi is playing, and even for that matter, the new stores, so that the government of India is very actively starting. So, it's very difficult to come to any conclusion. Maybe it will take some time before we know what's happening."

International: ARV Recovery and Canada Outperformance


Lenacapavir: A Long-Dated ARV Option with Prophylactic Upside

Samit Mehta: "I believe the potential of this product could possibly be far larger than the current ARV market. The reason being is, while today it is approved only as a treatment, I understand that trials are also going on for use of this molecule in a preventive or prophylactic indication. So, if that comes through, probably the market size itself will increase compared to where it is today."

Margins: Mix Pressure Now, Operating Leverage Later


Strategic Moves: Derma Subsidiary, Biosimilars Facility, and In-Licensing

Satish Mehta: "I am happy to announce that we have recently onboarded a new team in our Derma to grow that business. To give adequate focus to Derma, we have set up a new 100% owned subsidiary, Emcutix to grow that business."

Guidance & Commitments

CommitmentSpecificsTimeline
Full-year revenue growth20%+; on track to deliverFY25
2H margin improvement2H margins better than 1H; endeavour to improveFY25 2H
Interest cost reductionCome down by ~₹25 crores in second halfFY25 2H
PCPM targetReach high 6s territoryFY25 end
Lenacapavir development cycle18–24 months from tech pack to filingFrom tech-pack receipt
Organic international growthLow double digits, given geographic mixOngoing
Domestic growth aspirationSlightly faster than overall industry (high single digits)Ongoing
Europe growth targetDouble-digit growthGoing forward

Key Metrics

MetricQ2 FY25
Revenue from operations₹2,002 cr, +20% YoY
Domestic revenue₹933 cr, +15% YoY
Domestic revenue ex-FCM and ex-Sanofi+7–8% YoY and +3% QoQ
International revenue₹1,069 cr, +25% YoY; organic growth +14%
Canada revenue₹296 cr, +51% YoY
Europe revenue₹362 cr, +6% YoY
Emerging markets revenue₹411 cr, +29% YoY
Gross margin60.6%, vs 62.9% in Q2 FY24
EBITDA₹417 cr, +26% YoY
EBITDA margin20.8%, higher than Q2 FY24 and Q1 FY25
Base margin ex one-time other income+50 bps QoQ
PAT₹202 cr, +38% YoY
Depreciation and amortization₹97 cr, vs ₹70 cr YoY
Interest cost₹46 cr, includes ₹8 cr one-time prepayment expense
Estimated tax rate~26%
Net debt₹705 cr, down from ₹1,558 cr at start of fiscal year and ₹846 cr at end July
Working capital days~96 days at end September
Full-year revenue growth guidance20% plus
Full-year EBITDA margin guidance20% to 21%
PCPM (per contact per month)~6.6, vs 6.3 in Q1 FY25 and 5.9 in Q2 FY24
Domestic volume growth ex-Sanofi, ex-FCM3–4%
Domestic pricing growth ex-Sanofi, ex-FCM2–3%
Domestic new products contribution ex-Sanofi, ex-FCM2–3%
H1 Europe growth7%
Organic overall growth~12%
Interest cost reduction expected in H2~₹25 cr
Forex gains in other income~₹5 cr
Discontinued product (Etodolac + Paracetamol) contributionless than ₹10 cr
Mehsana oral solids facility utilizationcloser to 50%